Literature DB >> 57784

Electrocardiographic antecedents of primary ventricular fibrillation. Value of the R-on-T phenomenon in myocardial infarction.

N El-Sherif, R J Myerburg, B J Scherlag, B Befeler, J M Aranda, A Castellanos, R Lazzara.   

Abstract

Primary ventricular fibrillation was seen in 20 of 450 consecutive patients (4-4%) admitted within 24 hours after the onset of acute myocardial infarction. Compared with patients without primary ventricular fibrillation they showed a lower mean age group and a higher incidence of anterior infarction. Warning ventricular arrhythmias preceded primary ventricular fibrillation in 58% of cases. However, warning arrhythmias were also present in 55% of patients without primary ventricular fibrillation. The following mechanisms of initiation of primary ventricular fibrillation were seen. 1) In one patient, it was initiated by supraventricular premature beats showing aberrant intraventricular conduction. 2) In 2 patients, ventricular tachycardia degenerated into primary ventricular fibrillation. 3) In 17 patients, it was initiated by a ventricular premature beat; in 10 of these, the premature beat showed early coupling (RR/QT less than 1--the R-on-T phenomenon). However, ventricular premature beats showing the R-on-T phenomenon were also observed in 49% of patients without primary ventricular fibrillation. In 7, primary ventricular fibrillation was initiated by a late-coupled ventricular premature beat (RR/QT greater than 1); in 2, the very late coupling resulted in a ventricular fusion beat. The study suggests that warning arrhythmias and the R-on-T phenomenon are poor predictors of primary ventricular fibrillation in acute myocardial infarction. The observation that 41% of primary ventricular fibrillation was initiated by a late-coupled ventricular premature beat suggests that ventricular vulnerability during acute myocardial infarction may extend throughout most of the cardiac cycle and is not necessarily confined to the QT interval.

Entities:  

Mesh:

Year:  1976        PMID: 57784      PMCID: PMC483010          DOI: 10.1136/hrt.38.4.415

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  25 in total

1.  Medical reversal: why we must raise the bar before adopting new technologies.

Authors:  Vinay Prasad; Adam Cifu
Journal:  Yale J Biol Med       Date:  2011-12

2.  Ventricular ectopic activity after premature atrial beats in acute myocardial infarction.

Authors:  R J Myerburg; R J Sung; G Gerstenblith; S M Mallon; A Castellanos
Journal:  Br Heart J       Date:  1977-09

3.  [Drug therapy of tachyarrhythmias (author's transl)].

Authors:  K Theisen
Journal:  Klin Wochenschr       Date:  1978-02-15

4.  Ventricular arrhythmias in patients with recent myocardial infarction.

Authors:  J Erwin
Journal:  Ir J Med Sci       Date:  1990-04       Impact factor: 1.568

5.  Initiation of ventricular fibrillation by supraventricular beats in patients with acute myocardial infarction.

Authors:  S Bekheit; G Turitto; J Fontaine; N el-Sherif
Journal:  Br Heart J       Date:  1988-02

6.  QT dispersion ratio in patients with unstable angina pectoris (a new risk factor?).

Authors:  V G Cin; M Celik; S Ulucan
Journal:  Clin Cardiol       Date:  1997-06       Impact factor: 2.882

Review 7.  [Acute coronary syndrome in the prehospital phase].

Authors:  J-H Schiff; H R Arntz; B W Böttiger
Journal:  Anaesthesist       Date:  2005-10       Impact factor: 1.041

8.  A trial of prophylactic mexiletine in home coronary care.

Authors:  J A Bell; J M Thomas; J R Isaacson; N J Snell; D W Holt
Journal:  Br Heart J       Date:  1982-09

9.  Prophylaxis against ventricular arrhythmias in suspected acute myocardial infarction: a comparison of tocainide and disopyramide.

Authors:  R A Allen-Narker; C J Roberts; A J Marshall; S C Jordan; D W Barritt; R M Goodfellow
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

Review 10.  Clinical pharmacokinetics of lignocaine.

Authors:  N L Benowitz; W Meister
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.